We use Javascript to set most of our cookies. Unfortunately Javascript is not running on your browser, so you cannot change your settings using this page. To control your cookie settings using this page try turning on Javascript in your browser.
We use essential cookies to make this website work and additional cookies to optimise functionality and experience.
Analytics
Cookies that measure website use
We use industry-standard web analytics tool to measure how you use the website so we can improve it based on our user needs. These tools set cookies that store anonymised information about:
how you got to the site
the pages you visit on our site and how long you spend on each page
what you click while you are visiting the site
Marketing
Cookies that help with information and marketing
For the promotion of our services we may use retargeting cookies. They may be set by ourselves or third parties. These cookies allow us or the third parties to display promotional material (for example, advertisements) to you on other websites you visit, to measure the performance of promotional material and content, and derive insights about those who viewed them.
Personalisation
Cookies that remember your settings
These cookies do things like remember your preferences and the choices you make, to personalise your experience of using the site.
Necessary cookies
Strictly necessary cookies
These essential cookies do things like:
remember the notifications you’ve seen so we do not show them to you again
MeOmics Precision Medicine is a Cardiff‑based medtech company using stem‑cell derived human cellular models and advanced AI‑driven analysis to transform psychiatric drug discovery.
Established in 2021 as a spin‑out from Cardiff University, it builds on foundational research backed by an Innovate UK grant and supported in partnership with St Andrew’s Healthcare. Its platform identifies a patient’s biological type to enable safer, more precise psychiatric treatments, starting with conditions such as schizophrenia.
Leader
Lucy Sykes leads MeOmics as a female CEO operating at the intersection of deep‑tech, cell biology, and psychiatric medicine - a field where women remain notably underrepresented.
She is vocal about the challenges female leaders face, stressing the importance of equitable investment support and the urgent need for psychiatric data that reflects women and diverse patient groups.
Business purpose
MeOmics exists to address a longstanding issue in psychiatric medicine: treatments built on male‑centric biological data. This has historically resulted in widespread misdiagnosis, underdiagnosis, and less effective outcomes for women and other under‑represented populations.
The business generates clinically relevant human data that reflects population diversity, helping drug developers reduce clinical failure rates, improve safety, and match therapies to precise biological subtypes - similar to how precision oncology transformed cancer therapeutics.
Working with us (Funding)
The most recent funding round, during the 2025/26 period, totalled £300,000, combining £125,000 from Women Angels of Wales, £125,000 in match funding from the Wales Angel Co‑Investment Fund, and £50,000 from existing investors. It follows a £25,000 Smart Flexible Innovation Support (SFIS) grant from Welsh Government.
The investment allowed MeOmics to advance its precision psychiatry technology platform, expand data generation capabilities, hire additional technical staff, strengthen customer‑readiness and scale its commercial partnerships.
“The complexity of mental illnesses means it is difficult to develop new therapies that work for everyone. Our technology allows us to do in psychiatry what’s been done in oncology, helping drug developers match treatments to targeted groups of patients depending on their underlying biology.”
She further emphasises the gender representation challenge:
“Historically, data is biased towards men - in clinical trials and therapeutic development. To make the right decisions, we need data that represents women and the diverse patient population.”
Sara Boltman, Lead Investor, Women Angels of Wales, said: “When Lucy came to pitch to us, she was so enthusiastic about the problems MeOmics can solve with precision psychiatry. Leading this round was exciting, and having match funding gave them more firepower and runway.”
Carol Hall, Co‑Investment Network Manager at the Development Bank of Wales, added: “MeOmics Precision Medicine is an excellent example of the kind of business working in Wales’ medtech ecosystem. We were glad to back Women Angels of Wales’ investment in the business, and welcome Sara Boltman’s expertise as lead investor.”
The impact
MeOmics is contributing to a new era of precision psychiatry, enabling drug developers to reduce clinical risk, avoid harmful side effects for patients, and significantly improve treatment matching.
The latest funding round strengthens Wales’ growing medtech cluster and supports female leadership in a sector where representation remains low. The company is now positioned to accelerate commercialisation, deepen partnerships, and expand its scientific and technical team to meet global demand for biologically-grounded psychiatric drug discovery tools.
